Does Rallies show 13F holders for ALMS?

Yes. Rallies tracks hedge fund and 13F ownership data for ALMS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALMS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALMS. It does not provide personalized investment advice.

ALMS (Alumis Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Alumis Inc. Common Stock (ALMS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALMS trades at $22.66 with a market cap of $2.70B and a P/E ratio of -12.17. ALMS moved +2.37% today. Year to date, ALMS is +165.22%; over the trailing twelve months it is +351.64%. Its 52-week range spans $2.76 to $30.60. Analyst consensus is strong buy with an average price target of $40.44. Rallies surfaces ALMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALMS stock?

Hedge funds tracked by Rallies that own ALMS include Orbimed Advisors, Farallon Capital, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alumis Inc. Common Stock.

ALMS Key Metrics

Key financial metrics for ALMS
Metric	Value
Price	$22.66
Market Cap	$2.70B
P/E Ratio	-12.17
EPS	$-1.78
Dividend Yield	0.00%
52-Week High	$30.60
52-Week Low	$2.76
Volume	112
Avg Volume	0
Revenue (TTM)	$8.40M
Net Income	$-237.41M
Gross Margin	0.00%

Top Hedge Funds Holding ALMS

Orbimed Advisors holds 548.16K shares of ALMS, changed -50.29% as of Mar 31, 2026.
Farallon Capital holds 11.00K shares of ALMS, changed +0.00% as of Mar 31, 2026.
Eisler Capital holds 10.75K shares of ALMS, changed +0.00% as of Jun 30, 2024.

Latest ALMS News

Alumis’s Envudeucitinib Achieves 68% PASI 90 Response; Q1 Cash $569.5M — May 14, 2026
Alumis Prices $300M Upsized Offering of 17.65M Shares at $17 Each — Jan 8, 2026
Envudeucitinib Achieves 65% PASI 90 and Over 40% PASI 100 in Alumis Phase III Trials — Jan 8, 2026
Alumis Prices 17.65M-Share Offering at $17, Targeting $300M Proceeds — Jan 8, 2026
Alumis Raises $300M via 17.65M-Share Offering as Envudeucitinib Hits PASI 90 in 67% — Jan 8, 2026

Recent ALMS Insider Trades

AKKARAJU SRINIVAS bought 588.24K (~$10.00M) on Jan 9, 2026.
Foresite Labs, LLC bought 117.65K (~$2.00M) on Jan 8, 2026.
Foresite Labs, LLC bought 294.12K (~$5.00M) on Jan 8, 2026.

ALMS Analyst Consensus

9 analysts cover ALMS: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $40.44.

Common questions about ALMS

Who owns ALMS stock?: Hedge funds tracked by Rallies that own ALMS include Orbimed Advisors, Farallon Capital, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alumis Inc. Common Stock.
Does Rallies show 13F holders for ALMS?: Yes. Rallies tracks hedge fund and 13F ownership data for ALMS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALMS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALMS. It does not provide personalized investment advice.